The Role of Biomarkers in Diagnostics
Biomarkers are central to ovarian cancer detection. CA-125 is widely recognized, though its sensitivity is limited in early-stage disease. HE4 complements CA-125, and the ROMA algorithm combines multiple biomarkers for more reliable predictions.
Emerging biomarkers such as OVX1, PAX2, and MMP7 are under research for improved early detection. Combining biomarker analysis with imaging and genetic testing offers a comprehensive diagnostic approach, allowing better patient stratification and personalized care.
To explore current trends and developments, refer to the Ovarian
Cancer Diagnostics Market Size.
Imaging plays a crucial role in ovarian cancer diagnostics. Ultrasound is a primary tool for initial assessment due to its accessibility and non-invasive nature. CT and MRI offer detailed soft tissue imaging for accurate staging, while PET scans provide functional insights into tumor activity.
AI integration in imaging improves interpretation, detects subtle abnormalities, and supports early diagnosis. These advances are driving market growth and improving patient outcomes globally.